![Yehezkel Ben-Ari](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Yehezkel Ben-Ari
Direttore/Membro del Consiglio presso Institut National de la Santé & de la Recherche Médicale
Profilo
Yehezkel Ben-Ari is the founder of Neurokin SA, which was founded in 2003.
He held the title of Director from 2003 to 2014.
Currently, he is the Director at Institut National de la Santé & de la Recherche Médicale.
Posizioni attive di Yehezkel Ben-Ari
Società | Posizione | Inizio |
---|---|---|
Institut National de la Santé & de la Recherche Médicale
![]() Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France. | Direttore/Membro del Consiglio | 20/11/2009 |
Precedenti posizioni note di Yehezkel Ben-Ari
Società | Posizione | Fine |
---|---|---|
Neurokin SA
![]() Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | Fondatore | 11/03/2014 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Neurokin SA
![]() Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | Health Technology |
Institut National de la Santé & de la Recherche Médicale
![]() Institut National de la Santé & de la Recherche Médicale Miscellaneous Commercial ServicesCommercial Services Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France. | Commercial Services |
- Borsa valori
- Insiders
- Yehezkel Ben-Ari